Exploration of 2-benzylbenzimidazole Scaffold As Novel Inhibitor of NF-κB
Overview
Chemistry
Affiliations
For finding the novel inhibitor of nuclear factor κB activity, a series of benzimidazole derivatives were rationally designed, synthesized and systematically studied for their in vitro activities against LPS induced NF-κB inhibition in RAW 264.7 cells using the SEAP assay based on the flexible chalcone JSH ((E)-1-(2-hydroxy-6-(isopentyloxy)phenyl)-3-(4-hydroxy phenyl)prop-2-en-1-one) which was previously reported. Although most of the benzimidazole derivatives showed strong inhibitory activity in low micromolar potency, 2-(4-methoxybenzyl)-1H-benzo[d]imidazole (3m; IC50=1.7 μM) and 2-(2-methoxybenzyl)-1H-benzo[d]imidazole (3n; IC50=2.4 μM) showed the best inhibition. The structure activity relationship revealed that 2-benzylbenzimidazole scaffold with hydrogen bonding acceptor on phenyl ring appears as a pharmacophore.
Barakat A, Alshahrani S, Al-Majid A, Alamary A, Haukka M, Abu-Serie M Front Pharmacol. 2024; 15:1358089.
PMID: 38650632 PMC: 11033320. DOI: 10.3389/fphar.2024.1358089.
Ayoup M, Wahby Y, Abdel-Hamid H, Abu-Serie M, Ramadan S, Barakat A RSC Adv. 2023; 13(40):27722-27737.
PMID: 37736568 PMC: 10509784. DOI: 10.1039/d3ra04029a.
Patel M, Avashthi G, Gacem A, AlQahtani M, Park H, Jeon B Molecules. 2023; 28(14).
PMID: 37513362 PMC: 10384041. DOI: 10.3390/molecules28145490.
Pham E, Le Thi T, Ly Hong H, Vo Thi B, Vong L, Vu T RSC Adv. 2023; 13(1):399-420.
PMID: 36605630 PMC: 9782508. DOI: 10.1039/d2ra06667j.
Pham E, Thi Le T, Truong T RSC Adv. 2022; 12(33):21621-21646.
PMID: 35975065 PMC: 9347358. DOI: 10.1039/d2ra03491c.